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Resistance  of  cancer  cells  to chemotherapeutics  and  emerging  targeted  drugs  is  a devastating  problem  in
the treatment  of  cancer  patients.  Multiple  mechanisms  contribute  to  drug  resistance  such  as  increased
drug efﬂux,  altered  drug  metabolism,  secondary  mutations  in  drug  targets,  and  activation  of  downstream
or  parallel  signal  transduction  pathways.  The  rapid  kinetics,  the  reversibility  of  acquired  drug  resistance
and  the absence  of  genetic  mutations  suggest  an  epigenetic  basis  for drug  insensitivity.  Similar  to  the
cellular  variance  seen  in the  human  body,  epigenetic  mechanisms,  through  reversible  histone  modiﬁca-
tions  and  DNA methylation  patterns,  generate  a  variety  of transcriptional  states  resulting  in a  dynamic
heterogeneous  tumor  cell  population.  Consequently,  epigenomes  favoring  survival  in  the  presence  of
a drug  by  aberrant  transcription  of  drug  transporters,  DNA-repair  enzymes  and  pro-apoptotic  factors
render  cytotoxic  and targeted  drugs  ineffective  and  allow  selection  of  rare drug-resistant  tumor  cells.
Recent  advances  in charting  cancer  genomes  indeed  strongly  indicate  a  role  for  epigenetic  regulators  in
driving  cancer,  which  may  result  in  the  acquisition  of  additional  (epi)genetic  modiﬁcations  leading  to
drug resistance.  These  observations  have  important  clinical  consequences  as  they  provide  an  opportunity
for  “epigenetic  drugs”  to  change  reversible  drug-resistance-associated  epigenomes  to  prevent  or  reverse
non-responsiveness  to  anti-cancer  drugs.. Introduction
Resistance acquired upon drug treatment (“acquired drug resis-
ance”) is a major problem in the treatment of many diseases,
ncluding cancer. World-wide an estimated 7.5 million cancer
atients die each year, many of them due to failed anti-cancer
herapies as a consequence of acquired resistance to cytotoxic
hemotherapeutics and targeted drugs (Boyle and Levin, 2008).
hus, understanding the mechanisms causing unresponsiveness to
nti-cancer drugs will dramatically improve the design of ther-
pies aimed at preventing the selection of drug-resistant tumor
ells. Consequently, such therapies may  signiﬁcantly reduce can-
er mortality rates. With the rise of targeted drug therapies it has
ecome increasingly evident that genetic mutations are a criti-
al component of acquired drug resistance. However, genetics are
ot sufﬁcient in explaining the relatively rapid appearance or the
eversibility of non-responsiveness to drug treatment. In addition,
he lack of genetic mutations in drug targets and activated parallel
athways suggested a role for non-genetic mechanisms in acquired
rug resistance (Glasspool et al., 2006). This review will focus on
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the role of chromatin biology in tumorigenesis and in non-genetic
acquired drug resistance.
2. Tumor heterogeneity and epigenetics
Until now, several mechanisms underlying acquired drug
resistance have been uncovered including increased drug efﬂux,
enhanced drug metabolism, inactivation of apoptotic pathways,
secondary mutations in drug targets, and activation of downstream
or parallel pathways (Redmond et al., 2008). The basis for these
mechanisms has been attributed to increased genetic instability
and accelerated mutation rate in tumor cells providing genetic
diversity that allows selection of cells with a survival advantage
during drug treatment.
Although a genetic basis for acquired drug resistance con-
tributes to anti-cancer therapy failure, a number of observations
imply a non-mutational contribution to drug non-responsiveness.
First, the high prevalence of drug resistance suggests that acqui-
sition of mutations cannot solely account for this phenomenon.
Secondly, the reversibility of acquired drug resistance has been
Open access under CC BY-NC-ND license.described in patients receiving retreatment upon a drug-free
period. Third, a substantial number of drug-resistant tumors do not
harbor mutations in drug targets or activated pathways. Finally,
despite the notion that tumors arise through clonal expansion of
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ells that have acquired genetic alterations advantageous for pro-
iferation, survival and metastasis (Hanahan and Weinberg, 2011),
here is large variability in malignancy and drug resistance of indi-
idual cells (Gupta et al., 2011; Shipitsin et al., 2007). A basis for this
ariability may  be found in the different transcriptional network
tates produced by the same cancer genome, in a similar fashion
s transcriptional network states realize a variety of cell types in
he body by one genome. It has been suggested that reversible
ranscriptional network states controlled by DNA- and chromatin
odiﬁcations play a role in generating dynamic heterogeneity
equired for differentiation (Chang et al., 2008). Similarly, hetero-
eneity in a tumor cell population, based on dynamic variation in
pigenome conﬁgurations, is thought to provide a non-genetic vari-
nce source for selection of drug-resistant cells (Brock et al., 2009;
upta et al., 2011). Indeed, tumors exhibit extensive genetic and
on-genetic heterogeneity within the tumor cell population (Fraga
t al., 2005; Seligson et al., 2005).
A non-genetic basis for tumor cell heterogeneity and acquired
rug resistance has long been neglected. With the discovery of “can-
er stem cells” or “tumor-initiating cells”, tumor heterogeneity is
ore appreciated and has raised new questions with respect to
reatment outcome. Although many questions remain about the
oncept of tumor stem cells and their contribution to tumorigenesis
t has become evident that these cells are intrinsically more resis-
ant to various anti-cancer drugs, either by increased drug efﬂux,
nability to execute apoptosis, enhanced DNA repair, different pro-
ein dynamics or by displaying a quiescent cell-cycle state (Cohen
t al., 2008; Eyler and Rich, 2008; Frank et al., 2010). As epige-
etics has a crucial role in cell fate determination (Ji et al., 2010;
ikkelsen et al., 2007; Sarmento et al., 2004), it has been proposed
hat DNA and histone modiﬁcations may  drive non-genetic het-
rogeneity resulting in the establishment of tumor-initiating cells
nd/or drug-resistant cells (Feinberg et al., 2006).
Epigenetics, deﬁned as changes in gene expression that are inde-
endent of changes in the DNA sequence and persist over many
ell divisions, has been recognized as an important factor in gen-
rating non-genetic heterogeneity (Chang et al., 2008). Although
ene expression is controlled by multiple mechanisms, covalent
odiﬁcations of DNA and histones are at the heart of regulating
ene transcription. Epigenetic changes affect gene transcription
y modulating the packaging of chromatin, thereby regulating
he accessibility of DNA to sequence-speciﬁc transcription factors
ig. 1. Histone and DNA methylation enzymes involved in tumorigenesis and drug resistan
ail,  or histone core (H3K79) are targeted by methyltransferases (KMTs; in black) and d
C-rich nucleotide stretches and is modulated by DNA methyltransferases (DNMTs) and 
olor  in this ﬁgure legend, the reader is referred to the web  version of the article).istance Updates 15 (2012) 21– 38
(van Steensel, 2011). In addition, combinations of epigenetic marks
are “read” by specialized protein modules present in transcription
complexes, and are consequently “translated” into a biological out-
put such as switching on or off transcription (Taverna et al., 2007).
Ultimately, the readout of epigenome variation dictates the diver-
sity in cellular phenotypes of cells harboring the same genome. In a
similar fashion, a speciﬁc combination of genetic and epigenetic
marks may  produce a drug-resistant phenotype in a heteroge-
neous tumor cell population (Fig. 3A). In order to design therapies
aimed at preventing or reversing drug resistance it will be impor-
tant to identify epigenetic marks and their biological consequences
in drug-resistant tumor cells. In the ﬁrst part of this review we
focus on the link between tumorigenesis and post-translational
modiﬁcations of DNA and histones, in particular methylation and
acetylation (Table 1). In the second part we will discuss the role of
tumor cell epigenomes in mechanisms underlying drug resistance.
2.1. DNA methylation
DNA is predominantly methylated at cytosines (5-methyl-C;
5mC) by DNA methyltransferases (DNMT1, 3A, 3B and DNMT3L)
(Fig. 1) (Cedar and Bergman, 2011). While methylation at
transcribed regions or gene bodies is thought to facilitate tran-
scription elongation, methylation of promoter regions is in general
associated with gene silencing (Maunakea et al., 2010). Methylated
cytosines can serve as docking sites for methyl-binding proteins
which subsequently recruit co-repressor complexes resulting in
gene silencing (Jones et al., 1998; Nan et al., 1998). Other functions
besides gene regulation have been attributed to cytosine methy-
lation such as preventing chromosomal instability by methylation
of repetitive genomic sequences dispersed over the genome (Bird,
2002). Long-term silencing of genes is normally only associated
with inactive X-linked genes, imprinted genes and germ-cell-
speciﬁc genes. In particular, CpG islands, cytosine and guanine-rich
DNA sequences, are frequently hypermethylated in tumor cells
which can result in silencing of tumor suppressor genes (De  Smet
et al., 1999; Herman et al., 1994; Merlo et al., 1995).
The observation that indirect inhibition of DNA methyltrans-
ferases using the nucleoside analog 5-azacytidine (5-aza-CR)
resulted in re-expression of silenced genes and inhibited tumor cell
growth by inducing differentiation has resulted in the use of 5-aza-
CR (Vidaza) and 5-aza-dCR (Decitabine) as therapeutic agents in the
ce. Histone H3 and H4 lysine (K) and arginine (R) residues present in the N-terminal
emethylases (KDMs; in red). DNA methylation takes place at cytosine residues in
enzymes that modify methylated cytosines (for interpretation of the references to
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reatment of myelodysplastic syndromes (MDS). In addition, direct
nhibition of DNMTs using small molecule inhibitors targeting spe-
iﬁc DNMTs are being developed (Foulks et al., 2011). Despite their
linical efﬁcacy the clinical relevant transcriptional targets of these
ompounds remain unclear.
Studies in mice and men  suggested that reduction or muta-
ional inactivation of DNMTs may  have adverse effects. Mice
xpressing reduced levels of Dnmt1 developed with high inci-
ence thymic lymphomas due to hypomethylation of pericentric
eterochromatin, suggesting that reduced Dnmt1 levels may
esult in chromosome missegregation and consequently genomic
nstability (Gaudet et al., 2003). Although no DNMT1 mutations
ave been identiﬁed in human malignancies, DNTM3B mutations
re associated with the immune deﬁciency, centromere instability
nd facial anomalies (ICF) syndrome. In addition, elevated levels of
NMT3B have been observed in tumors, in part due to ampliﬁcation
f DNMT3B (Simó-Riudalbas et al., 2011). Moreover, the discovery
f highly recurrent, heterozygous somatic DNMT3A mutations in
DS  and acute myeloid leukemia (AML), which are correlated with
oor prognosis, provides another cautionary note on inhibiting
NMTs in anti-cancer therapy (Ley et al., 2010). Acquired drug
esistance has been associated with selection of cells displaying
ypomethylation of drug efﬂux gene promoters, hypermethylation
f promoter regions of pro-apoptotic genes, or altered promoter
ethylation patterns of DNA-repair genes (see below). In addition,
he poor prognosis proﬁle of MDS  and AML  patients carrying
omatic DNMT3A mutations may  attest to increased acquired
rug resistance due to DNA methylation changes that generate
ells with a drug resistance favorable epigenome. Therefore,
haracterization of a drug-resistance-associated DNA methylome
ay  guide the design of therapeutics aimed at targeting DNA
ethylation either through 5mC  nucleoside analogs or direct and
ndirect inhibitors of DNMTs.
.2. DNA demethylation
Until now, DNA demethylases have not been identiﬁed and DNA
emethylation is thought to occur through passive dilution dur-
ng replication. However, active mechanisms have been discovered
hich prime 5mCs by hydroxylation, deamination and/or oxida-
ion, which are subsequently removed by DNA-repair mechanisms.
hree enzyme families are known to be involved in active demethy-
ation (Fig. 1). Priming of the methylated cytosines is conducted
y ten-eleven translocation (TET1, 2 and 3) enzymes to form 5-
ydroxy methyl cytosine (5hmC), the function of which has not
een fully characterized (Bhutani et al., 2011). Intriguingly, TET2
s a frequent target of mutations in hematopoietic malignancies
uggesting that one TET family member has a tumor suppressor
unction possibly by affecting 5hmC modiﬁcations and generating
 (locally) hypermethylated cancer epigenome (Delhommeau et al.,
009; Langemeijer et al., 2009). Cytidine deaminases (AID/APOBEC)
re a second class of enzymes able to modify 5mC  or 5hmC into 5-
ethyluracil or 5-hydroxymethyluracil. Eventually, replacement of
he intermediate forms of methylated cytosines into unmethylated
ytosines is initiated by the UDG family of base excision repair (BER)
lycosylases (TDG/SMUG1). Since hyper- and hypomethylation of
romoter regions is involved in drug resistance, studies aimed at
orrelating modiﬁed methylation of cytosine and prognosis upon
reatment may  provide a hint whether the enzymes involved in
enerating modiﬁed forms of 5mC  are involved in unresponsive-
ess to drugs.. Histone modiﬁcations
A vast variety of biological processes ranging from gene tran-
cription to DNA repair are regulated at the nucleosomes, the basicistance Updates 15 (2012) 21– 38 23
unit of chromatin consisting of DNA and an octamere of small
basic histone proteins (H2A, H2B, H3 and H4). The interaction
between DNA and histone proteins is tightly regulated by his-
tone modiﬁcations predominantly at the N-terminal tails of histone
proteins extruding from the nucleosome core (Figs. 1 and 2).
Post-translational modiﬁcations (PTMs) of histones are diverse,
reversible and delicately balanced by an expanding set of histone-
modifying enzymes. Currently known histone modiﬁcations exist
in many forms and include acetylation, methylation, phospho-
rylation, propionylation, butyrylation, N-formylation, ubiquityla-
tion, sumoylation, citrullination, proline isomerization, and ADP
ribosylation (Cohen et al., 2011). The recent identiﬁcation of 67
previously unknown PTM sites in histones as well tyrosine hydrox-
ylation and lysine crotonylation indicates the vast complexity that
can be achieved by combinations of histone PTMs (Tan et al., 2011b).
3.1. Lysine acetylation
Acetylation of lysine residues at histone tails is catalyzed by
lysine acetyl transferases (KATs), also known as histone acetyl
transferases (HATs; for nomenclature see Allis et al., 2007). Acetyl
groups neutralize the positive charge of lysines, resulting in a loose
DNA-nucleosome association that increases DNA accessibility for
transcription factors and subsequent transcriptional activity. KATs
are divided in three major families based on sequence similari-
ties: GNAT-, p300/CBP- and the MYST family. Additional KATs have
been identiﬁed and are classiﬁed as a separate group of enzymes
due to their sequence divergence from other KATs (Sadoul et al.,
2011). Although KATs are predominantly located in the nucleus, an
increasing number of studies report nucleocytoplasmic transport
of these enzymes suggestive of cytoplasmic substrates and func-
tions for KATs (Sadoul et al., 2011). Indeed, the identiﬁcation of
numerous acetylation sites in approximately 2000 proteins sup-
ports the notion that KATs regulate also the acetylation status of
a large number of non-histone proteins (Choudhary et al., 2009;
Zhao, 2010).
Several KATs have been implicated in tumorigenesis. KAT2
(GCN5) activated the BRCA1 and TP53 tumor suppressors as well
as the oncogenic activity of c-MYC (Gamper and Roeder, 2008;
McMahon et al., 2000; Oishi et al., 2006). KAT8 (MOF) is known
to acetylate TP53 at lysine residue 120 (K120) together with KAT5
(TIP60) (Sykes et al., 2006; Tang et al., 2006). Furthermore, loss
of histone H4 lysine 16 acetylation (H4K16ac), which is speciﬁ-
cally regulated by KAT8, is a common hallmark of human cancer
(Fraga et al., 2005; Taipale et al., 2005) (Fig. 2). KAT3A (CREBBP)
and KAT3B (EP300) regulate the function of TP53, RB, E2F and MYB
proteins, which play an important role in tumorigenesis (Chan
et al., 2001; Gu and Roeder, 1997; Martínez-Balbás et al., 2000;
Tomita et al., 2000). These ﬁndings were further corroborated
by studies in KAT3A and KAT3B mutant mice which show that
KAT3A and -3B can act as tumor suppressors of hematological
malignancies (Kung et al., 2000). Moreover, KAT3A and -3B
loss-of-function mutations were identiﬁed in various human can-
cers (Bryan et al., 2002; Kishimoto et al., 2005; Miller and
Rubinstein, 1995; Muraoka et al., 1996). In addition, oncogenic
translocations involving KAT3A and KAT3B have been observed
in hematological malignancies such as AML, myeloid/lymphoid
or mixed lineage leukemia (MLL) (Iyer et al., 2004). KAT3A point
mutations were also identiﬁed in acute lymphoblastic leukemia
(ALL) and bladder cancer (Gui et al., 2011; Pasqualucci et al.,
2011). Interestingly, analysis of relapsed ALL found KAT3A muta-
tions in 18.3% of non-responders, which were either present at
diagnosis or acquired at relapse. Several mutations acquired at
relapse were detected in sub-clones at diagnosis, suggesting that
the mutations may  confer resistance to therapy (Mullighan et al.,
2011). These results suggest that inactivation of KAT3A and KAT3B
24 R.H. Wilting, J.-H. Dannenberg / Drug Resistance Updates 15 (2012) 21– 38
Fig. 2. Histone acetylation sites and enzymes linked to tumorigenesis and drug resistance. Lysine acetyl transferases (KATs; in black) target various lysine residues at the
histone H3 and H4 N-terminal tail or histone core (H3K56). Acetylated lysines are deacetylated by histone deacetylases (HDACs and SIRTs; in red) (for interpretation of the
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ay  change the epigenomic landscape of cancer cells thereby pro-
oting tumorigenesis and resistance in ALL. Indeed, acetylation of
ysine 18 on histone H3 (H3K18ac) was impaired in cells express-
ng tumor-associated mutant KAT3A (Fig. 2). Interestingly, loss of
3K18ac is correlated with tumor grade and poor prognosis in
atients with prostate, pancreatic, lung, breast and kidney can-
er (Elsheikh et al., 2009; Manuyakorn et al., 2010; Seligson et al.,
009; Seligson et al., 2005). Moreover, H3K18 hypoacetylation is
ssociated with an increased risk of tumor recurrence in patients
ith low-grade prostate cancer (Seligson et al., 2005), suggesting
hat this histone modiﬁcation may  be involved in acquired drug
esistance. In contrast, studies in esophageal squamous cell carci-
oma and glioblastoma patients correlated H3K18 hypoacetylation
ith better prognosis, suggesting that H3K18ac status may  effect
umorigenesis or drug sensitivity in a cell-type-dependent manner
Liu et al., 2010; Tzao et al., 2009).
.2. Lysine deacetylation
Acetylation of lysine residues is counteracted by histone
eacetylases (HDACs), which restore the positive charge of lysine
esidues resulting in a tightly packed chromatin conﬁguration
nd subsequently transcriptionally inactive gene regions. Based on
equence homology HDACs can be divided in four classes: class
 HDACs (HDAC1, 2, 3, and 8) are homologous to Sacchromyces
erevisae Rpd3, class II HDACs (HDAC4, 5, 6, 7, 9, 10) share high
omology with yeast Hda1, while HDAC11 is the sole member of
lass IV HDACs and shares homology with both classes (Gao et al.,
002; Gregoretti et al., 2004; Haberland et al., 2009; Yang and Seto,
008). Class III HDACs are homologous to yeast Sir2 and require
AD+ as a cofactor for deacetylation, in contrast to class I, II and
V HDACs, which hydrolyze acetyl groups using Zn2+ as a cofactor
Haigis and Guarente, 2006). HDACs are present in distinct protein
omplexes associated with gene repression such as NuRD, SIN3A,
o-REST (HDAC1 and 2) and SMRT/N-CoR (HDAC3) (Yang and Seto,
008). Class I HDAC complexes also harbor other histone-modifyingrticle).
enzymes such as histone demethylases KDM1, KDM4A and KDM5A
(Klose et al., 2007; Shi et al., 2004; Tong et al., 1998; You et al., 2001;
Zhang et al., 2005). Although no HDAC mutations have been iden-
tiﬁed in human cancers, hypoacetylation is a hallmark of various
human malignancies. Global loss of H4K16ac occurs in various pri-
mary tumors simultaneously with loss of trimethylation at histone
H4 lysine 20 (H4K20me3) and DNA hypomethylation (Figs. 1 and 2)
(Fraga et al., 2005; Seligson et al., 2005). Furthermore, H4K16ac
loss correlates with tumor progression and it is associated with
chemotherapy resistance (Elsheikh et al., 2009; Fraga et al., 2005;
Hajji et al., 2010). The prognostic value of elevated levels of SIRT1,
a H4K16ac targeting deacetylase, in various cancers may  therefore
relate to the induction of drug resistance (Chen et al., 2005; Hida
et al., 2007; Huffman et al., 2007) (Fig. 2).
Class I HDACs are recruited by a variety of oncogenic fusion
proteins involved in hematological malignancies, including PML-
RAR and AML-ETO (Amann et al., 2001; Gelmetti et al., 1998;
Grignani et al., 1998). The observation that many proteins involved
in tumorigenesis, such as TP53, RB, E2F1 and oncogenic fusion
proteins are modiﬁed by HDAC-controlled acetylation underscores
the role of HDACs as regulatory proteins during tumorigenesis.
Moreover, increased levels of HDAC2, responsible for deacetyla-
tion of histone H3 lysine 56, and histone H4 lysines K5, K8, K12
and K16, were observed upon loss of the adenomatosis polyposis
coli (APC) tumor suppressor gene in a mouse colon cancer model
(Fig. 2). Inhibition of HDACs using valproic acid (VPA) reduced the
number of adenomas in these mice, suggesting a tumor-initiating
role for HDAC2 in colon cancer. HDAC3, which deacetylates his-
tone H3 lysines K9 and K14, and histone H4 lysines K5, K12
and K16, is implicated in tumorigenesis by virtue of its bind-
ing to the transcriptional corepressor NCOR which in turn binds
BCL6, a protein frequently mutated in diffuse B-cell lymphoma
(DBCL) (Ahmad et al., 2003; Bhaskara et al., 2008; Bi and Ye, 2010)
(Fig. 2). Besides recruitment of HDAC3 by oncogenic fusion pro-
teins, HDAC3 is frequently deleted in breast cancer and MDS  (Ebert,
2009; Johannsdottir et al., 2006). Moreover, liver-speciﬁc deletion
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f HDAC3 in mice increased the incidence of hepatocellular carci-
oma (HCC), suggesting a tumor suppressive function for HDAC3,
robably by inducing genomic instability (Bhaskara et al., 2008).
Targeting HDACs using small molecule inhibitors such as tricho-
tatin A (TSA), sodium butyrate (NaBu) and valproic acid (VPA) was
hown to induce differentiation and apoptosis of a variety of tumor
ell lines (Richon et al., 1998). Ultimately, these observations let
o the FDA approval of the HDAC inhibitor (HDACi) SAHA (Vorinos-
at/Zolinza) for the treatment of cutaneous T-cell lymphoma (CTCL)
nd romidepsin (Istodax) for the treatment of CTCL and periph-
ral T-cell lymphoma (PTCL) (Coifﬁer et al., 2012; Prince et al.,
009). In addition, a variety of HDACi are currently being tested as a
onotherapy or in combination with existing anti-cancer therapies
f various human malignancies.
.3. Histone methylation
While acetylation is found exclusively at lysine residues, his-
one methylation occurs at lysine and arginine residues of the
istone tails. In contrast to acetylation and phosphorylation, his-
one methylation does not substantially change the amino acid
harge, but does increase their hydrophobicity. Histone methyla-
ion leads to activation or repression depending on which residues
re modiﬁed and the number of methyl groups present. These
istone methylation states exhibit a genome-wide distribution pat-
ern in which combinations of marks are linked to transcriptionally
ctive regions, for instance monomethylation of H3K9 (H3K9me)
nd trimethylation of H3K4 (H3K4me3), while others associate
ith repression of transcription, such as trimethylation of H3K9
H3K9me3) and H3K27 (H3K27me3) (Fig. 1) (Barski et al., 2007).
n embryonic stem cells bivalent modiﬁcation patterns exist, con-
isting of large areas of repressive H3K27 methylation harboring
maller regions of activating H3K4 methylation, which repress gene
ranscription, but keep these genes poised for action. These bivalent
omains are seen as a mechanism in which the chromatin state con-
rols cellular plasticity and thereby determines cell fate (Bernstein
t al., 2006; Mikkelsen et al., 2007). This suggests that global his-
one modiﬁcation patterns could be involved in tumorigenesis and
herefore may  play a role in speciﬁc characteristics of tumor cells,
uch as drug resistance (Feinberg et al., 2006).
.3.1. Arginine methylation
Methylation of histones is performed by protein arginine
ethyltransferases (PRMTs) and lysine methyltransferases (KMTs).
he family of PRMTs consists of 11 enzymes, of which PRMT1, 4, 5
nd 6 are known histone methyltransferases. Compared to lysine
ethylation, arginine methylation is under-explored and therefore
ittle is known about the inﬂuence of histone arginine methylation
n cancer and drug resistance (Bedford and Clarke, 2009). Never-
heless, PRMT1 was identiﬁed as an essential component of the
LL-oncogenic fusion proteins, highlighting the role of arginine
ethyltransferases in tumorigenesis (Cheung et al., 2007). Others
ave identiﬁed PRMT5 as an arginine methyltransferase affecting
he target gene speciﬁcity of TP53 and apoptosis (Jansson et al.,
008). In addition, PRMT5 seems to act as a SNAIL co-repressor of
-cadherin thereby inducing epithelial–mesenchymal transition, a
allmark of metastasis (Hou et al., 2008). Indeed, overexpression
f PRMT5 induces anchorage-independent growth and elevated
RMT5 levels are found in gastric and hematological malignan-
ies (Kim et al., 2005; Wang et al., 2008). Moreover, high levels
f dimethylated H4R3, a mark for active transcription, correlated
ith poorly differentiated prostate cancer and were associated, in
ombination with other histone marks, with poor patient prognosis
nd tumor recurrence (Seligson et al., 2005). In contrast, oncogenic
AK2 kinases were shown to phosphorylate and inactivate PRMT5
esulting in global reduction of H2A/H4R3 methylation suggestingistance Updates 15 (2012) 21– 38 25
a context-dependent function of PRMT5 in tumorigenesis (Liu et al.,
2011) (Fig. 1).
3.3.2. Lysine methylation
Lysine methylation, predominantly at the N-terminus of histone
tails, is regulated by a large number of histone/lysine methyl-
transferases (HMTs/KMTs) and lysine demethylases (KDMs). An
increasing number of these proteins is found mutated, overex-
pressed or mislocated in human malignancies.
Although no mutations so far have been identiﬁed in KMT1A or
KMT1B (SUV39H1/2), which speciﬁcally trimethylate H3K9 (Fig. 1),
both proteins have been linked to tumorigenesis by their ability
to physically interact with the retinoblastoma tumor suppressor
(RB) and repress promoters by recruiting heterochromatin protein
1 (HP1) (Nielsen et al., 2001). Association of KMT1A and the onco-
genic pro-myeloid leukemia/retinoic acid receptor fusion protein
suggests a tumor promoting function in leukemia (Carbone et al.,
2006). In mice, simultaneous inactivation of KMT1A and KMT1B
resulted in profound chromosomal instability and consequently
B-cell lymphomagenesis (Peters et al., 2001). A tumor suppres-
sive function for KMT1A was  further supported by the observation
that KMT1A plays a critical role in providing thymocytes with an
H3K9me3-dependent senescence fail-safe mechanism to inhibit
oncogenic transformation upon oncogenic insults. Furthermore,
KMT1A seems to determine the cellular response upon treatment
with chemotherapeutics; loss of KMT1A prevents activation of a
senescence checkpoint, suggesting that H3K9 methylation may
be a critical determinant of acquired drug resistance (Braig et al.,
2005).
Recurrent ampliﬁcations of genomic regions harboring the
KMT1E (SETDB1) H3K9 methyltransferase (Fig. 1) have been identi-
ﬁed in melanomas carrying BRAFV600E mutations. Using a zebraﬁsh
melanoma model it was shown that KMT1E collaborates with onco-
genic BRAF in driving melanomagenesis probably by regulating
HOX gene expression (Ceol et al., 2011). Another member of the
SET methyltransferase gene family, KMT3A (SET2D) a histone H3
lysine 36 (H3K36) methyltransferase (Fig. 1), was recently found to
be inactivated in clear cell renal cell carcinoma (ccRCC) (Dalgliesh
et al., 2010; Sun et al., 2005).
KMT6 (EZH2), a H3K27 methyltransferase (Fig. 1), which is
part of the polycomb repressive complex 2 (PRC2) is consid-
ered an oncogene as it is overexpressed in various solid tumors
and is associated with invasion and progression of tumors (Kleer
et al., 2003; Min  et al., 2010; Varambally et al., 2002; Wagener
et al., 2010). Indeed, primary prostate cancer samples displayed
a tumor-speciﬁc H3K27me3 genome-wide pattern, which corre-
lated with repression of genes involved in embryonic stem cell
biology and with poor prognosis (Yu et al., 2007). Notably, also loss
of H3K27me3 has been observed in various human malignancies
such as prostate, ovarian, breast and pancreatic cancer and corre-
lated with poor prognosis (Wei  et al., 2008). Although these results
may  seem contradictive, increased or reduced H3K27me3 may
have context-dependent consequences. Moreover, other substrates
besides H3K27me3 may  play a signiﬁcant role in speciﬁc tumor
types. Nevertheless, in general, aberrant H3K27 trimethylation cor-
related with poor prognosis of patients. A possible mechanism
underlying the role of KMT6 and H3K27me3 in tumorigenesis
could be silencing of tumor suppressor genes. Indeed, overex-
pression of KMT6 resulted in H3K27me3-mediated repression of
tumor suppressors including CDKN2A, CDKN2B, CDKN1B, CDKN1C,
CDH1, DAB2IP, BRCA1 and ADRB2 (Bracken and Helin, 2009; Cao
et al., 2008; Gonzalez et al., 2009; Min  et al., 2010; Ougolkov
et al., 2008; Yang et al., 2009). Surprisingly, massive parallel DNA
sequencing of follicular lymphoma (FL) and the germinal cen-
ter subtype of diffuse large B-cell lymphoma (DLBCL) revealed
somatic KMT6 mutations (Morin et al., 2010). Although initially
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onsidered loss-of-function, a recent study indicated a dominant
ole for tumor-associated KMT6 mutations. KMT6Y641N,F in the
resence of wild-type KMT6 resulted in decreased afﬁnity for
n- and monomethylated H3K27 and enhanced conversion of
imethylated into transcription repressive trimethylated H3K27.
n line with these results, increased H3K27 trimethylation was
ound in tumor samples carrying tumorigenic KMT6 mutations
Yap et al., 2011). These ﬁndings are another demonstration of
enetic mutations in chromatin-modifying enzymes generating
ltered epigenomes that will affect a variety of biological processes
ncluding those involved in drug sensitivity.
KMT2 family enzymes (SET1A-B, MLL  and ASH1) are respon-
ible for the methylation of histone H3 at lysine 4 (H3K4) (Fig. 1).
rimethylation of H3K4 is associated with active gene transcription.
ene rearrangement of MLL  (KMT2A-E) is one of the most common
hromosomal abnormalities in human leukemia (Chi et al., 2010;
rivtsov and Armstrong, 2007). As a result of in frame chromo-
omal translocations, the MLL  N-terminus is fused to one of more
han 50 partners, including members of the AF and ENL family of
roteins, such as AF4, AF9, AF10, and ENL (Krivtsov and Armstrong,
007). Multiple studies have shown a tumor-initiating role of
hese fusion proteins by regulating the expression of HOX genes,
hich results in blocking differentiation and stimulating onco-
enic transformation (Chi et al., 2010). MLL-fusion proteins interact
irectly or indirectly with KMT4 (DOT1L), a histone H3 lysine 79
H3K79) methyltransferase and drive acute myeloid leukemia in a
MT4 methyltransferase activity dependent manner (Okada et al.,
005; van Leeuwen et al., 2002) (Fig. 1). Interaction of oncogenic
LL-fusion proteins and KMT4 resulted in an increase of H3K79
ethylation at promoters and concomitant upregulation of tran-
cription of leukemia-relevant genes including HOXA9 (Okada et al.,
005). Recently, a KMT4 small molecule inhibitor (EPZ004777) was
hown to selectively eradicate leukemic cells bearing the MLL  gene
ranslocation while having little effect on non-MLL-translocated
ells (Daigle et al., 2011). Furthermore, administration of the KMT4
nhibitor increased to some extent the survival of mice xenografted
ith a MLL  tumor cell line, indicating that inhibition of the his-
one modiﬁer KMT4 may  serve as a targeted therapeutic against
LL. The possibility of treating leukemia harboring oncogenic MLL-
usion proteins with epigenetic drugs took an exiting turn with
he development of small molecule inhibitors targeting members
f the bromodomain and extraterminal (BET) subfamily of human
romodomain proteins (BRD2, BRD3 and BRD4) (Filippakopoulos
t al., 2010). Bromodomain-containing proteins associate with
cetylated chromatin and facilitate transcriptional activation by
ecruiting transcriptional activators including MLL-fusion part-
ers (Dawson et al., 2011). BET-inhibitors (BET-i) were shown
o be effective against mouse and human MLL-fusion leukemias
y inducing cell-cycle arrest and apoptosis. Mechanistically, BET-
 inhibited transcription of cancer relevant genes such as BCL2,
-MYC and CDK6, through displacement of BET proteins from chro-
atin (Dawson et al., 2011; Delmore et al., 2011; Zuber et al.,
011). The notion that many human malignancies require the onco-
rotein C-MYC for tumor maintenance provides opportunities for
ET-inhibitors as epigenetic drugs in the treatment of a variety of
umors (Delmore et al., 2011; Soucek et al., 2008).
.4. Lysine demethylation
Histone methylation is counteracted by lysine-speciﬁc
emethylases (KDMs). Two classes of histone demethylases
ave thus far been identiﬁed. KDM1A (LSD1) and KDM1B (LSD2)
omprise the KDM1 class, which are FAD-dependent amine oxi-
ases and demethylate only mono- and dimethylated lysines.
he Jumonji C (JmjC) domain is a signature motif for the sec-
nd class of demethylases, which consists of 30 Fe(II) andistance Updates 15 (2012) 21– 38
2-oxoglutarate-dependent enzymes. Proteins in this class are
subdivided based on JmjC domain sequence homology and the
overall architecture of additional motifs (Pedersen and Helin,
2010). Demethylase activity has been observed for several of
these proteins, of which the majority targets methylated lysines,
although JMJD6 demethylates histone H3 arginine 2 (H3R2) and
histone H4 arginine 3(H4R3) (Chang et al., 2007) (Fig. 1).
Similar to histone methyltransferases, aberrant function of his-
tone demethylases is associated with cancer, indicating that a
balanced control of chromatin conﬁguration is imperative for nor-
mal  cell growth. For example, downregulation of KDM1 (LSD1),
a subunit of the NuRD transcriptional repressive complex, was
observed in breast carcinomas and may  correlate with metastatic
potential of these tumors (Wang et al., 2009b).  However, in spe-
ciﬁc tissues, such as in the prostate and testis, KDM1 is present in a
chromatin-associated complex together with the androgen recep-
tor (AR) and demethylates the repressing histone marks mono-
and dimethyl H3K9 and thereby promotes gene activation of AR
target genes (Metzger et al., 2005) (Fig. 1). These observations
suggest a role for KDM1 in androgen responsive tissues such as
brain, prostate and testis. Indeed, KDM1 expression correlated with
aggressive prostate cancer possibly by constitutive activation of AR-
mediated growth signals (Kahl et al., 2006). Furthermore, others
found strong expression of KDM1 in poorly differentiated neu-
roblastoma (Schulte et al., 2009). Inhibition of KDM1 using small
molecule inhibitors or KDM1 shRNAs increased H3K4 methylation
and inhibited tumor growth (Metzger et al., 2005) (Fig. 1). In addi-
tion, KDM1 was  found to suppress TP53 activity by demethylation
of dimethylated TP53 lysine 370, thereby preventing interaction
between TP53 and 53BP1 (Huang et al., 2007). These results
suggest that KDM1 can either repress or activate gene transcrip-
tion, depending on the proteins it interacts with, underlining the
ambiguous nature of KDMs.
While KDM1 removes mono- and dimethyl groups, jumonji
domain containing demethylases remove mono-, di- and trimethyl
groups (Klose and Zhang, 2007). Mislocalization of jumonji domain
demethylases has been observed in various cancer types. A sub-
set of AML  patients presented with chromosomal translocations
involving nucleoporin 98 (NUP98) and the H3K4me2/3 recognizing
PHD motif of KDM5A (JARID1A/RBP2) or PHF23 (Wang et al., 2009a)
(Fig. 1). The oncogenic potential of such fusion proteins relies on
the PHD-motif-mediated H3K4me2/3 recognition and the inabil-
ity to remove this histone mark as well as concomitant inhibition
of KMT6-mediated H3K27 trimethylation (H3K27me3) (Fig. 1). The
increase in H3K4me2/3 and reduction of H3K27me3 subsequently
enforces the expression of genes critical for hematopoietic devel-
opment leading to leukemia (Cui et al., 2009; Wang et al., 2009a).
Recently, direct evidence was provided showing that increased
KDM5A levels were sufﬁcient to acquire resistance to cytotoxic and
targeted drugs (Sharma et al., 2010).
KDM5B (JARID1B/PLU-1) overexpression was found in advanced
stages of prostate cancer and breast cancer where it induced
the removal of H3K4me2/3 leading to repression of several
tumor suppressor genes, including BRCA1 (Xiang et al., 2007b;
Yamane et al., 2007) (Fig. 1). Repression of tumor suppres-
sor genes by histone demethylases seems to be a recurrent
theme, since KDM2B (JHDM1B/FBXL11) erased dimethylation
of H3K36me2 and/or H3K4me3, leading to repression of the
p14ARF, p15INK4B and p16INK4A cell inhibitory protein encoding
CDKN2A/B locus in T-cell lymphomas (He et al., 2008; Tzatsos
et al., 2009) (Fig. 1). In agreement with the role of this locus as
an anti-tumorigenic fail-safe mechanism, expression of KDM2B
and the related KDM2A (JHDM1A/FBXL10) inhibit replicative- and
oncogene-induced senescence, thereby promoting tumorigenesis.
In addition to misregulation of KDMs by overexpression and
chromosomal translocation, somatic inactivating mutations of
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Table 1
Histone modiﬁcations and related modifying enzymes associated with tumorigenesis, patient prognosis and drug resistance.
Histone modiﬁcation Enzymes Relative level in cancer Role in cancer References
H3K9ac KAT2, KAT12, SIRT6 Reduction Tumor progression Seligson et al. (2005)
Poor patient prognosis Park et al. (2008)
Zhen et al. (2010)
Good patient prognosis Barlési et al. (2007)
H3K14ac KAT2, KAT3, KAT6, KAT7, KAT10, KAT12 Reduction Drug resistance Sharma et al. (2010)
H3K18ac KAT2, KAT3, KAT12 Reduction Tumor progression Seligson et al. (2005)
Tumor recurrence Seligson et al. (2005)
Poor patient prognosis Manuyakorn et al. (2010)
Good patient prognosis Tzao et al. (2009)
H3K56ac KAT3B Gain Tumorigenesis Liu et al. (2010)
H4K16ac KAT5, KAT8, SIRT1, SIRT2 Reduction Drug resistance Hajji et al. (2010)
Transformation Fraga et al. (2005)
H2A/H4R3me2 PRMT1, PRMT5 Gain Tumor recurrence Seligson et al. (2005)
Poor patient prognosis Seligson et al. (2005)
Reduction Tumorigenesis Barlési et al. (2007)
H3K4me2/3 PRMT6, Reduction Drug resistance Sharma et al. (2010)
KMT2, KMT7, KDM1, KDM2, KDM5 Tumor recurrence Seligson et al. (2005)
Poor patient survival Manuyakorn et al. (2010)
H3K9me2/3 KMT1, KMT8, KDM1, KDM3, KDM4 Gain Invasion, metastasis Bracken et al. (2007)
Poor patient prognosis Chen et al. (2010)
Drug resistance Braig et al. (2005)
Reduction Poor patient survival Manuyakorn et al. (2010)
H3K9me3 KMT1, KMT8, KDM3, KDM4 Gain Tumor progression Bachman et al. (2003)
Tumor recurrence Nguyen et al. (2002)
Poor patient prognosis Nguyen et al. (2002)
Good patient prognosis Ye et al. (2007)
H3K27me3 KMT6, KDM6 Reduction Senescence Shen et al. (2007)
Poor patient prognosis Wei  et al. (2008)
Gain Apoptosis Müller-Tidow et al. (2010)
Pluripotency Wu et al. (2010b)
Poor patient prognosis Yu et al. (2007)
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DM6A (UTX) have been found in various tumors, particularly
n multiple myeloma and ccRCC (Dalgliesh et al., 2010; van
aaften et al., 2009). Both KDM6A and KDM6B (JMJD3) were
hown to have H3K27me3 demethylating activity (Agger et al.,
007) (Fig. 1). Therefore, the tumorigenic potential of KDM6A
utations may  relate to the inability to remove the repressive
3K27me3 mark at distinct genomic loci (van Haaften et al., 2009).
n addition, KDM6B contributed to the activation of the CDKN2A
ocus (expressing p16Ink4a and p14Arf/p19Arf) upon oncogenic BRAF
nd RAS expression, suggesting that inactivation of H3K27me3
emethylases may  inactivate a tumor protective fail-safe mech-
nism (Agger et al., 2009). Indeed, downregulation of KDM6B
xpression levels was found in various hematological malignan-
ies. In contrast, others have reported overexpression of KDM6B in
odgkin’s lymphoma and prostate cancer progression (Anderton
t al., 2011; Xiang et al., 2007a)  suggesting that KDM6B may  have
ell-type-speciﬁc substrates, which require either gain- or loss-
f-function to provide a proliferative selective advantage during
umorigenesis.
Inactivating somatic KDM5C (JARID1C/SMCX) mutations were
iscovered in primary ccRCC. In these tumors, KDM5C muta-
ions predominantly co-occurred with mutations in the Von
ippel–Lindau (VHL) tumor suppressor, and correlated with the
ranscriptional alteration of a speciﬁc ccRCC gene signature
Dalgliesh et al., 2010).Finally, the jumonji-only histone demethylase KDM8 (JMJD5),
n H3K36me2 demethylase was shown to be overexpressed in
reast, thyroid, adrenal, bladder, uterine, and liver related can-
ers (Hsia et al., 2010) (Fig. 1). Inhibition of KDM8 in breast cancerTransformation Fraga et al. (2005)
cell lines resulted in a cell-cycle arrest, suggesting that KDM8 is
essential for tumor cell proliferation. Mechanistically, KDM8 was
shown to compete with class I HDACs in transcriptional regu-
lation. Demethylation of H3K36me2, a repressive mark, resulted
in loss of HDAC1 chromatin binding and consequently increased
histone acetylation and active transcription of proliferation genes
such as cyclin A1 (Hsia et al., 2010). While these results suggest a
tumor-promoting function for KDM8, others identiﬁed KDM8  loss-
of-function retroviral integrations in murine B-cell lymphomas.
Consistent with studies in C. elegans (Pothof et al., 2003), down-
regulation of KDM8 in ﬁbroblasts resulted in an increased mutation
frequency, suggesting that KDM8, at least in this setting, suppresses
genome instability and can be considered a tumor suppressor
(Suzuki et al., 2006).
4. Epigenetics and drug resistance
Histone PTMs are recognized by proteins harboring one
or more specialized structures, such as chromo-(methylation),
bromo-(acetylation), BCRT-(phosphorylation) and PHD-domains
(methylation) (Chi et al., 2010). Among these proteins are SWI/SNF,
ISWI, CHD and INO80 chromatin remodeling proteins, which in turn
move, destabilize, eject or restructure nucleosomes, thereby chang-
ing chromatin structure and adding an extra layer of regulation
(Clapier and Cairns, 2009). The combination of DNA and histone
modiﬁcations provides an enormous non-genetic diversity allow-
ing a level of speciﬁcity that is required for the execution of a variety
of biological processes including cell-type-speciﬁc transcription,
replication and DNA repair (Baylin and Jones, 2011). Intriguingly,
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ecent efforts in mapping genetic alterations by whole genome
r exome sequencing of a variety of human malignancies yielded
vidence that DNA- and histone-modifying enzymes as well as
ucleosome remodelers are frequently mutated and contribute to
umorigenesis (Delhommeau et al., 2009; Gui et al., 2004; Jiao et al.,
011; Jones et al., 2010; Langemeijer et al., 2009; Ley et al., 2010;
ikoloski et al., 2010; Pasqualucci et al., 2011; van Haaften et al.,
009; Varela et al., 2011; Versteege et al., 1998; Wang et al., 2009a).
hese studies not only establish a critical role for epigenetics as a
riving force in tumorigenesis but also provide a rational for epige-
omic changes and non-genetic heterogeneity observed in tumor
ells (Table 1). The establishment of tumor epigenomes not only ini-
iates tumorigenesis but also allows the acquisition of additional
enetic and epigenetic changes that deregulate many biological
rocesses including those favoring survival in the presence of a par-
icular drug. Moreover, “misinterpretation” of chromatin states by
utated PTM readers will contribute to transcriptional states that
nduce non-genetic drug resistance. The dependency of such tran-
criptional states on reversible histone modiﬁcations encourages
he design and development of epigenetic drugs to reverse tumor
pigenomes to a state that is incompatible with cellular life or a
rug responsive state.
Mechanisms involved in acquired drug resistance are increased
rug efﬂux, inactivation of pro-apoptotic genes, perturbed DNA
epair, activation of parallel or downstream signal transduction
athways and secondary mutations in drug targets. Although these
echanisms are associated with genetic alterations, several stud-
es indicated a role for DNA and histone modiﬁcations in driving
ncreased drug efﬂux, silencing of apoptotic genes and perturbed
NA repair (Table 1; Fig. 3B).
. Multidrug resistance by epigenetic regulation of ABCB1
Increased expression of P-glycoprotein (Pgp; ABCB1) is a well-
nown mechanism involved in acquired drug resistance (Borst and
lferink, 2002; Sarkadi et al., 2006). Pgp belongs to the ATP binding
assette (ABC) transporter superfamily, which facilitates increased
fﬂux of chemotherapeutic drugs from tumor cells resulting in drug
nsensitivity to various agents (Senior et al., 1995). Tumors with
ntrinsically low expression levels of Pgp generally respond well to
hemotherapy. Expression of the Pgp encoding gene ABCB1 or Multi
rug Resistance 1 (MDR1)  is often induced upon chemotherapy,
ollowed by subsequent upregulation of ABCB1 protein expression
Baker et al., 2005; Hu et al., 1999). Treatment of murine Brca1−/−;
53−/− breast cancer with doxorubicin, docetaxel or the poly (ADP-
ibose) polymerase inhibitor olaparib, resulted in acquired drug
esistance correlating with upregulation of Abcb1 RNA levels (Pajic
t al., 2009; Rottenberg et al., 2007). Additional treatment of this
urine breast cancer model with the topoisomerase inhibitor
opotecan resulted in acquired drug resistance due to upregulation
f the Bcrp/Abcg2 drug transporter. Genetic deletion of Abcg2/Bcrp
n the Brca1−/−; p53−/− mouse breast cancer indeed increased the
verall survival of topotecan treated animals, but did not eradi-
ate tumors indicating that additional mechanisms are involved in
cquired drug resistance (Zander et al., 2010). Studies in patients
ith AML  revealed that drug treatment induced ABCB1 expression
as observed already 4 h upon the start of chemotherapy (Hu et al.,
999). Moreover, in four out of ﬁve patients with unresectable pul-
onary metastases, increased ABCB1 mRNA levels were detected
nly 50 min  after doxorubicin treatment (Abolhoda et al., 1999). In
ddition, progressive drug resistance correlated with the increase
f ABCB1 expression and the intensity of the chemotherapy in neu-
oblastoma (Keshelava et al., 1998). In conclusion, the kinetics and
ose-dependent induction of ABCB1 upon drug treatment favors aistance Updates 15 (2012) 21– 38
role for immediate transcriptional activation of ABCB1 over selec-
tion of a tumor subpopulation expressing high ABCB1 levels.
The question remains, which factors cause the induction of
ABCB1 expression and in particular which chromatin changes at
the promoter region affect ABCB1 expression upon drug treatment?
Hypo- and hypermethylated DNA has been found at the ABCB1
promoter in different (tumorigenic) contexts. While the ABCB1 pro-
moter in normal bladder cells is hypomethylated, tumor cells of this
tissue usually contain a hypermethylated ABCB1 promoter. Inter-
estingly, upon chemotherapy, methylation of the ABCB1 promoter
reverted to its hypomethylated state and correlated with overex-
pression of the ABCB1 gene in tumors of the bladder and similar
observations were made in AML  patient samples (Nakayama et al.,
1998; Tada et al., 2000). Hypomethylation of the promoter of the
ABCG2/BCRP drug transporter also increased expression in response
to chemotherapy, suggesting that this is a general mechanism to
regulate ABC transporter expression in response to drug treatment
(Bram et al., 2009).
How chemotherapeutic drugs induce hypomethylation of the
ABCB1 promoter is still not fully understood and different mecha-
nisms have been postulated (Baker and El-Osta, 2004). For instance,
chemotherapeutic drugs could induce active DNA  demethylation
by yet unknown DNA demethylases. Alternatively, chemothera-
peutics could select for a small tumor subpopulation harboring
hypomethylated ABCB1 promoters. A model involving passive
demethylation has been proposed in which tethering of methy-
lases involved in DNA methylation (such as DNMT1) to the DNA
is inhibited, resulting in a lack of methylation. Finally, changes
in key chromatin remodeling complex activities could have an
impact on the methylation status of the ABCB1 promoter, or lead to
alleviated repression at the ABCB1 promoter, resulting in induced
ABCB1 expression. There are indications that histone-modifying
complexes are recruited to the methylated ABCB1 promoter serving
its transcriptional repression. For instance, MeCP2, a well-known
Methyl-CpG-binding protein (MBP) (Nan et al., 1997), binds to
hypermethylated DNA at the ABCB1 promoter (El-Osta et al., 2002)
and may  serve as a docking platform for nucleosome modiﬁers
and remodelers, such as SWI/SNF, HDAC1, HDAC2 and mSIN3,
thereby altering the chromatin state of gene promoters and sub-
sequently transcription (Harikrishnan et al., 2005; Jones et al.,
1998; Nan et al., 1998). Although a direct interaction of these co-
repressors with the ABCB1-promoter-bound MeCP2 has not been
described, ABCB1 expression is induced upon inhibition of HDAC
activity or by overexpression of the p300/CREB lysine acetyl trans-
ferase (KAT3B) (Baker et al., 2005; Jin and Scotto, 1998; Tabe
et al., 2006). While HDACi treatment had a relative small effect on
ABCB1 expression in human T-cell acute lymphoblastic leukemia
cells, combined inhibition of DNA methylation and HDAC activ-
ity did induce ABCB1 expression, supporting a repressive role of
the MeCP2/HDAC complex in regulation of ABCB1 expression (El-
Osta et al., 2002). Removal of HDAC inhibition dramatically reduces
ABCB1 protein level, albeit with slow kinetics over a time period of
6 days, suggesting that other factors are involved in regulation of
ABCB1 expression (Xiao et al., 2005).
In response to HDACi treatment acetylation levels of histones
H3 and H4, and methylation levels of H3K4 were increased at the
ABCB1 promoter (Baker et al., 2005; Xiao et al., 2005). In analogy,
H3 acetylation, but not H4 acetylation and H3K4 methylation, was
increased at the ABCB1 promoter upon chemotherapy and preceded
the ABCB1 expression, suggesting that H3 promoter acetylation
is involved in drug-treatment-induced ABCB1 expression (Baker
et al., 2005). In contrast, trimethylation of H3K4 at the ABCB1 pro-
moter was found to be dependent on the methyltransferase KMT5A
(MLL1). Knockdown of KMT5A decreased the constitutive expres-
sion of ABCB1 and sensitized cancer cells to chemotherapeutic
agents (Huo et al., 2010).
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In addition to ABCB1,  breast cancer resistance protein (BCRP) and
ultidrug-resistance-associated protein 8 (MRP8) expression lev-
ls are also found upregulated upon HDACi treatment (Hauswald
t al., 2009). These ﬁndings suggest that HDACs are recruited to
he methylated promoter and mediate transcriptional repression
f drug transporters, including ABCB1,  BCRP and MRP8.
Collectively these data indicate that drug-treatment-induced
BCB1 expression occurs at the transcriptional level, which is medi-
ted by DNA methylation and histone acetylation at the ABCB1
romoter and can contribute to acquired resistance to anti-cancer
herapies (Fig. 3B).
. Epigenetic silencing of pro-apoptotic genes in drug
olerance
Drug treatment in anti-cancer therapy often leads to tumor cell
eath, i.e. apoptosis. Genetic or epigenetic perturbations resulting
n a defective execution of an apoptotic response could potentially
esult in drug-tolerant tumor cells. Indeed, genetic mutations as
ell as epigenetic changes in pro-apoptotic genes are a hallmark of
uman malignancies (Hanahan and Weinberg, 2011). Although it
emains controversial whether these mutations contribute to drug
esistance (Borst et al., 2001), stochastic epigenetic silencing of pro-
poptotic genes in a fraction of the total tumor cell population may
llow selection of these cells upon drug treatment. Indeed, sev-
ral pro-apoptotic genes were found to be silenced by promoter
ethylation upon drug treatment including death associated pro-
ein kinase 1 (DAPK1) and apoptotic peptidase activating factor 1
APAF-1).
Cell-cycle arrest or apoptosis are promoted by tumor sup-
ressor gene TP53 in response to chemotherapy treatment, and
s a consequence TP53 loss can induce drug resistance. Caspase-
 and its cofactor Apaf-1 are essential downstream effectors of
53 during Myc-induced apoptosis. Consistently, inactivation of
aspase-9 and Apaf-1 can substitute for the loss of p53 in Myc-
riven oncogenic transformation (Soengas et al., 1999). Indeed,
oss of APAF-1 expression is frequently observed in metastatic
elanomas retaining TP53. APAF-1 negative melanoma cells were
nable to execute an apoptotic program in response to TP53 acti-
ation, resulting in chemotherapy resistance. Loss of APAF-1 in
etastatic melanoma occurred through genomic loss or epigenetic
ilencing. In the latter case APAF-1 expression was restored by
he DNA-methylation inhibitor 5-aza-dCR resulting in enhanced
hemosensitivity and rescue of the apoptotic defects associated
ith APAF-1 loss (Soengas et al., 2001). In addition, others have
eported increased APAF-1 expression in ovarian cancer cell lines
reated with HDACi, suggesting a contribution in APAF-1 silenc-
ng by HDACs (Tan et al., 2011a).  Surprisingly, APAF-1 negative
elanoma cells did not display hypermethylation of the APAF-
 promoter indicating that APAF-1 expression is regulated by an
ndirect DNA-methylation-dependent mechanism (Soengas et al.,
001). While APAF-1 promoter methylation was  not apparent in
ultiple myeloma (Chim et al., 2007), transitional cell carcino-
as  of the bladder and ccRCC harbored hypermethylated APAF-1
romoters which correlated with tumor stage and tumor grade
Christoph et al., 2006a; Christoph et al., 2006b). In conclusion,
ownregulation of pro-apoptotic APAF-1 expression is corre-
ated with resistance to chemotherapeutics, yet the mechanism
nderlying APAF-1-mediated drug resistance seems to be depend-
nt on cell type and TP53 status (Fig. 3B).
Reduced expression or inactivation of the pro-apoptotic DAPK1
y genetic or epigenetic mechanisms is found in human malig-
ancies (Michie et al., 2010; Raval et al., 2007). DAPK kinases
nduce apoptosis by phosphorylating serine and threonine residues
n substrates contributing to apoptosis induced by interferon-,istance Updates 15 (2012) 21– 38 29
FAS, tumor necrosis factor- (TNF), TNF-related apoptosis-
inducing ligand (TRAIL) and anoikis (Michie et al., 2010). In
addition, DAPK1 suppresses MYC- and E2F-induced oncogenic
transformation by activating p19ARF-p53-dependent apoptosis
(Raveh et al., 2001). Furthermore, DAPKs play a critical role
in inhibiting cell migration and invasion of cancer cells (Kuo
et al., 2006). Reintroduction of DAPK expression suppressed the
metastatic potential of lung cancer in a mouse model underlin-
ing the tumor suppressing capabilities of the DAPKs (Inbal et al.,
1997).
Loss of DAPK1 expression in tumors is caused by either homozy-
gous gene deletion, loss of heterozygosity or hypermethylation of
a CpG region in the 5′ UTR (Bialik and Kimchi, 2004). Epigenetic
silencing of DAPK was  found in the majority of sporadic chronic
lymphocytic leukemia (CLL) (Raval et al., 2007). These results were
supported by DAPK1 promoter methylation in a wide range of
human tumor types in which DAPK silencing correlated with tumor
progression, histo-pathological staging, increased metastasis and
high tumor recurrence (Bialik and Kimchi, 2004; Chaopatchayakul
et al., 2010; Christoph et al., 2006b; Raval et al., 2007; Sugita
et al., 2011; Tada et al., 2002; Toyooka et al., 2003; Voso et al.,
2010). However, in AML  and MDS  the extent of DAPK promoter
methylation is a matter of debate since some studies identiﬁed
this as a very rare event, contradicting previous studies (Claus
et al., 2011; Voso et al., 2010). DAPK expression could be restored
in tumor cells by demethylating agent 5-aza-dCR or HDACi, indi-
cating that DAPK silencing involves DNA-methylation and histone
acetylation (Christoph et al., 2006b; Toyooka et al., 2003; Wu
et al., 2010a; Zhang et al., 2006). A higher prevalence of DAPK,
FAS and TRAILR1 promoter hypermethylation in cervical carcino-
mas non-responsive to drug treatment suggested that epigenetic
downregulation of DAPK expression in part may contribute to
drug resistance (Chaopatchayakul et al., 2010). Indeed, HDACi-
mediated restoration of DAPK expression in human gastric and lung
cancer cell lines increased chemosensitivity to anti-cancer drugs
(Wu et al., 2010a; Zhang et al., 2006). In conclusion, the use of
epigenetic drugs capable of restoring DAPK expression, in com-
bination with DNA-damaging agents, is an exciting approach in
the treatment of DAPK negative, chemoresistant cancers (Fig. 3B
and C).
7. Epigenetic regulation of DNA-repair genes in drug
tolerance
Inactivation of mismatch repair genes (MMR)  leads to unre-
paired deletions in mono- and dinucleotide repeats resulting in
variable repeat lengths, referred to as microsatellite instability
(MSI), a hallmark of tumors with inactivated MMR  genes (Aaltonen
et al., 1993). Germline mutations of mismatch repair genes such
as MSH2, MLH1 and PMS2 are frequently found in hereditary non-
polyposis colon cancer (HNPCC) (Lynch et al., 2009). MMR  deﬁcient
human cancer cell lines tolerated alkylating agents, suggesting that
loss of MMR  could cause chemotherapy resistance (Anthoney et al.,
1996). MSI  in tumors can only in part be explained by mutations
in MMR  genes such as MLH1,  MSH2,  MSH3 and PMS2 (Peltomäki,
2003). In less than 10% of all sporadic uterine endometrial carci-
nomas (UEC) MSI  was  associated with mutations in MMR  genes,
suggesting that mutations in genes regulating MMR  proteins or
epigenetics could contribute to inactivation of MMR  gene expres-
sion. Indeed mutations affecting MSH2 protein degradation were
identiﬁed in a variety of cancers including ALL and colon can-
cer (Diouf et al., 2011). Epigenetic-driven inactivation of MMR
was illustrated by the identiﬁcation of MLH1 promoter hyperme-
thylation in various tumors and as an early event in endome-
trial tumorigenesis, which correlated with drug resistance and
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redicted poor overall survival (Esteller et al., 1998; Strathdee et al.,
999). However, an association between clinical response and MMR
tatus in primary tumors was not observed (Helleman et al., 2006),
ven though MLH1 silencing was correlated with tumor relapse
uring chemotherapy (Gifford et al., 2004).
The ability to measure MLH1 promoter methylation status in
lasma DNA from ovarian cancer patients provided a non-invasive
ethod to monitor the potential acquisition of drug resistance dur-
ng drug treatment (Gifford et al., 2004). Examination of plasma
NA of patients with epithelial ovarian cancer for methylation of
he MLH1 promoter before chemotherapy and at relapse revealed
ncreased MLH1 promoter methylation at relapse. Moreover, 25%
f the samples from patients with a relapse had MLH1 methylation
hat was not detected in matched prechemotherapy plasma sam-
les. Acquisition of MLH1 methylation in plasma DNA at relapse
redicted poor overall survival of patients (Gifford et al., 2004).
hese results strongly suggest that selection favors tumor cells with
epressed MLH1 during chemotherapy resulting in a drug-resistant
umor, which provides a rational for the use of epigenetic drugs to
estore MLH1 expression and abolish drug resistance (Fig. 3B and
).
O6-methylguanine DNA-methyltransferase (MGMT) encodes
he DNA-repair O6-alkylguanine-DNA-alkyltransferase (AGT),
hich removes alkylating lesions at position O6 of guanine
Verbeek et al., 2008). DNA damage induced MGMT expression
acilitates DNA repair and is a possible mechanism to acquire
esistance against alkylating agents. Overexpression of MGMT  in
arious mouse model studies suppressed tumor development due
o enhanced DNA damage repair (Gerson, 2004). In contrast, MGMT
nockout mice displayed increased sensitivity toward alkylating
hemotherapeutics providing genetic evidence for a role of MGMT
n drug responsiveness (Glassner et al., 1999). Although the precise
echanism of DNA-damage-induced MGMT  expression is still
nclear (Gerson, 2004; Verbeek et al., 2008), the MGMT  promoter
egion contains transcription factor recognition sequences that
xplain induction of MGMT  expression by glucocorticoids, cyclic
MP  and protein kinase C activators. Hypermethylation of speciﬁc
pG regions in the MGMT  promoter resulting in the silencing of
GMT  expression has been described in primary human tumors,
uch as glioma, lymphoma, retinoblastoma, breast and prostate
umors (Esteller et al., 1999; Kang et al., 2002; Watts et al.,
997). Remarkably, a reduction of MGMT  promoter methylation
as acquired upon chemotherapy treatment resulting in MGMT
xpression, and increased AGT activity rendering the cytotoxic
rugs ineffective (Chan et al., 1992; Fritz and Kaina, 1992). In line
ith these results, studies in patients with glioma, glioblastoma,
on-Hodgkin lymphoma or male germ cell tumors identiﬁed
GMT  promoter methylation as a marker for chemotherapy
ensitivity: tumor cells with hypermethylated MGMT promoters
esponded better to chemotherapy, and these patients showed
mproved survival compared to patients with hypomethylated
GMT  promoters (Esteller et al., 2000; Koul et al., 2004; Weller
t al., 2010). As a result, MGMT  promoter methylation status is an
stablished molecular marker in clinical trials, which is predictive
or the response to alkylating chemotherapy and radiotherapy
Kesari et al., 2009; Riemenschneider et al., 2010; Weller et al.,
010; Wick et al., 2009). In conclusion, elevated MGMT  expression,
aused by MGMT  promoter hypomethylation is a strong mediator
f acquired drug resistance, suggesting that MGMT silencing or AGT
nhibition has the potential to sensitize tumors for chemotherapy
Fig. 3B and C).
Another DNA-repair pathway that is linked to chemotherapy
esistance involves the Fanconi anemia (FA) group of proteins.
A germline mutations result in chromosomal instability leading
o congenital defects, bone marrow failure and increased cancer
usceptibility (D’Andrea, 2010). The Fanconi-BRCA1/2 molecularistance Updates 15 (2012) 21– 38
pathway plays an important role in DNA repair and is necessary
for the normal cellular response to interstrand DNA cross-linking
agents like cisplatin, mitomycin C and diepoxybutane (D’Andrea,
2010). Until now, 15 FA proteins have been identiﬁed, of which
eight assemble into a core complex upon DNA damage (Kim et al.,
2011; Stoepker et al., 2011). Monoubiquitination of FANCD2 and
FANCI results in chromatin recruitment into nuclear DNA-repair
foci. In addition, recruitment of the core complex by FANCM to
the site of DNA damage results in BRCA1/2- (BRCA2 is also known
as FANCD1) mediated DNA repair via homologous recombination
(Deans and West, 2011).
Somatic mutations or epigenetic silencing of the FA pathway is
observed in a variety of tumors (D’Andrea, 2010; Tischkowitz et al.,
2003). Fancf deﬁciency causes increased ovarian tumor incidence in
mice and in mouse embryonic ﬁbroblasts it resulted in an aberrant
response to DNA cross-linking agents (Bakker et al., 2012). Hyper-
methylation of the FANCF promoter was found in primary ovarian
adenocarcinomas, ovarian granulosa-cell tumors, cervical cancer,
non-small cell lung cancers (NSCLC) and squamous-cell head and
neck cancers (Dhillon et al., 2004; Marsit et al., 2004; Narayan et al.,
2004; Taniguchi et al., 2003). In ovarian, glioma and pancreatic can-
cer cell lines, FANCF promoter methylation resulted in decreased
gene expression and was  associated with increased sensitivity to
cisplatin and other DNA cross-linking agents (Chen et al., 2007;
Taniguchi et al., 2003). Conversely, restoration of FANCF expres-
sion by 5-aza-dCR-mediated promoter hypomethylation resulted
in cisplatin resistance (Taniguchi et al., 2003). In conclusion, treat-
ment of cancer patients with DNA cross-linking agents, such as
cisplatin and alkylating agents may  result in tumor relapse by selec-
tion for FANCF expressing tumors cells with hypomethylated FANCF
promoters (Fig. 3B). Measuring promoter methylation status of FA
genes during chemotherapy may  therefore be a suitable approach
to monitor drug resistance (D’Andrea, 2010).
Evidently, epigenetic regulation of genes involved in drug efﬂux,
apoptosis and DNA repair contributes to acquired drug resistance.
However, the chromatin biology underlying the epigenetic regu-
lation remains largely unknown. Consequently, manipulating the
expression of such genes to improve drug sensitivity or reverse
drug resistance is restricted. Future studies aimed at decoding
drug-resistance-associated histone marks, corresponding histone
modiﬁers and nucleosome remodelers will increase our knowledge
of critical players in epigenetic-driven drug resistance.
8. Chromatin-mediated drug resistance
Although the non-genetic transcriptional changes seen in drug-
resistant tumors, as described above, are clearly linked to altered
epigenetic regulation of genes, the underlying epigenetic mech-
anisms are largely unknown (Glasspool et al., 2006). While
the treatment of chronic myeloid leukemia (CML), harboring
the BCR–ABL fusion oncogene, with the targeted drug imatinib
(Gleevec) shows unprecedented clinical efﬁcacy and increased sur-
vival, a third of the patients require alternate therapy due to
non-responsiveness of the tumor cells (Roychowdhury and Talpaz,
2011; Sellers, 2011). Secondary mutations in BCR–ABL, which ren-
der imatinib ineffective (Gorre et al., 2001), can only explain drug
resistance to imatinib in 30% of the cases. The relative short time in
which drug resistance to imatinib occurs (<1 year) combined with
upregulation of relevant ERK and AKT pathways suggest a role for
non-genetic heterogeneity driving drug resistance.
A similar pattern is observed in the treatment of melanomas
harboring BRAFV600E mutations with BRAF inhibitors (PLX4032).
Despite an initial response, virtually all patients develop resistance
due to reactivation of the RAF–MEK pathway, activation of alter-
native signaling pathways or chromatin regulating events (Bollag
R.H. Wilting, J.-H. Dannenberg / Drug Resistance Updates 15 (2012) 21– 38 31
Fig. 3. Reversible non-genetic tumor heterogeneity as a source for drug resistance. (A) Tumors consist of a heterogeneous cell population, which display different drug
sensitivities. Whereas the bulk of the tumor cell population is sensitive toward drug treatment (light shaded population) rare populations of cells exhibiting either non-
reversible, genetic drug resistance (orange population) or reversible, non-genetic drug resistance (dark green population) are present before treatment. (B) Treatment of a
heterogeneous tumor cell population with cytotoxic or targeted drugs will eradicate the majority of tumor cells (light shaded). A rare subpopulation of tumor cells (dark green
in  A and B) will survive due to non-genetic drug resistance. Mechanisms implicated in non-genetic drug resistance include epigenetic changes resulting in gene transcription
of  drug transporters (ABCB1) pro-apoptotic genes (DAPK, APAF-1), DNA-repair proteins (MLH1, MGMT,  FANCF)  and histone modiﬁers (KDM5A). In addition, a reduction in
H3K4me and H3K14ac histone marks has been observed in drug-resistant cells, which may  be linked to MEK and IGF-1R signal transduction pathway activation. In addition,
cells  harboring (secondary) genetic changes in drug targets or parallel pathways (orange population) will be maintained in the drug-resistant population. Withdrawal of the
drug  treatment resulting in a drug-free period (“drug holiday”) may  restore susceptibility for the primary cytotoxic/targeted therapy by reversal of drug-resistance-associated
epigenetic marks. Alternatively, in the absence of the selective pressure of the drug, cells harboring an epigenome that enforces a proliferative advantage and drug sensitivity
will  grow out. (C) Treatment of non-genetic drug-resistant tumor cell populations with cytotoxic or targeted drugs in combination with epigenetic drugs, such as inhibitors of
histone  deacetylases (HDACi), DNA methyl transferases (DNMTi), histone methyltransferases (EPZ004777) and bromodomain proteins (BET-i) may  reverse a drug-resistant
epigenome into a drug sensitive epigenome thereby rendering tumor cells sensitive to the cytotoxic/targeted drug. Still, hard-wired genetic resistant tumor cells may  arise
(orange  cell population). (D) In order to prevent the latter cells to arise upon treatment, a drug regimen may  be used in which a cytotoxic drug is combined with an epigenetic
drug.  The rational for using this treatment plan is to debulk the tumor by cytotoxic drugs, killing the majority of the tumor cell population. Moreover, using this approach
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t al., 2010; Flaherty, 2010; Johannessen et al., 2010; Sharma et al.,
010; Smalley, 2010). Similar observations have been made in
he treatment of NSCLC carrying epidermal growth factor receptor
EGFR) activating mutations, with EGFR tyrosine kinase inhibitors
TKI). Remarkably, NSCLC patients who experienced a “drug hol-
day” upon developing EGFR TKI resistance responded well to
etreatment with EGFR TKI (Becker et al., 2011; Kurata et al., 2004;
ano et al., 2005). These observations suggested a reversible, epi-
enetic basis for the EGFR TKI resistance phenotype (Fig. 3A and
).
Indeed, a recent study provided intriguing mechanistic insight
nto the epigenetics underlying acquired resistance for EGFR TKI,
uch as erlotinib and geﬁtinib in NSCLC (Sharma et al., 2010).
lthough EGFR TKI or chemotherapeutics were very effective in
radicating the majority of NSCLC tumor cells carrying an activat-
ng EGFR mutation, a very small percentage (0.3%) of rare, quiescent
ells survived TKI treatment even at drug concentrations 100 times
he IC50. Interestingly, this rare drug-resistant cell population was
bserved in a variety of tumor cell lines upon cytotoxic and targeted
rug treatment ranging from 0.3 to 5.5% of the total population,
uggesting that non-genetic-mediated drug resistance may  be a
idespread mechanism across various malignancies and treatment
odalities.
Although the resistant cells, dubbed “drug-tolerant persisters”
DTPs) were enriched for CD133 and CD24 stem cell markers,
niformity of expression was lost as soon as DTPs resumed pro-
iferation in the presence of TKI. Proliferating DTPs (referred to
s DTEPs, “drug-resistant expanded persisters”) displayed a stem
ell marker expression proﬁle, which reﬂected the heterogeneity
f the parental tumor cell line. Whether DTPs can be consideredreatment with an epigenetic drug may sensitize surviving cells to a targeted drug,
cluding genetic resistant cells (for interpretation of the references to color in this
cancer stem cells or have functional cancer stem cell properties
remains unclear. Using a genetic mouse mammary tumor model,
it was shown that cisplatin-treated tumor remnants that allow
regrowth of the mammary tumors were not enrichment for tumor-
initiating cells (TICs; deﬁned by CD24 and CD49f mammary stem
cell markers), suggesting that TICs do not provide a mechanism for
drug resistance (Pajic et al., 2010). Prolonged low dose cisplatin
treatment of mouse mammary tumors in another mouse model
did result in the enrichment of CD29; CD24 double positive TICs
in cisplatin resistant tumors. Although these opposite results may
relate to experimental differences it is also conceivable that rapid
and dynamic epigenetic variations may  drive the transition of TICs
into more differentiated tumor cells and vice versa (Gupta et al.,
2011).
A non-mutational basis for EGFR TKI drug resistance was  sug-
gested by the frequency at which DTPs exist in a heterogeneous
tumor cell population (0.3–5.5%), the absence of secondary muta-
tions in EGFR (like T790M), ERBB3 activation or MET ampliﬁcation,
and de novo appearance of DTPs in single cell derived tumor
cell line clones. Moreover, prolonged passaging of DTEPs in drug-
free medium restored TKI sensitivity and therefore implied a
reversible, possibly epigenetic-based drug resistance. Comparative
gene expression analysis of the parental tumor cell line and DTEPs
revealed a non-random distribution of differential expressed genes,
suggesting global chromatin changes in the resistant cells. Sharma
et al. (Sharma et al., 2010) identiﬁed KMD5A (also known as JARID1A
and RBP2) among the genes speciﬁcally upregulated in DTEPs.
KMD5A is a histone demethylase that demethylates H3K4me2/3,
which is a histone modiﬁcation that marks open chromatin
and active genes (Christensen et al., 2007; Iwase et al., 2007;
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lose and Zhang, 2007; Secombe et al., 2007) (Fig. 1). In con-
ordance, EGFR TKI resistant cells displayed reduced H3K4me2/3,
 histone mark correlated with poor prognosis (Seligson et al.,
005).
Notably, others identiﬁed enrichment of KDM5B (JARID1B)
xpressing, slow cycling cells upon treatment of melanoma cells
ith cytotoxic- or BRAFV600E-targeted drugs. Interestingly, KDM5B
xpression marked a dynamic, temporarily distinct tumor subpop-
lation of slow-cycling cells, which were essential for tumor growth
Roesch et al., 2010). These results suggest that the H3K4 demethy-
ases KDM5A and KDM5B both contribute to non-genetic tumor
eterogeneity and drug resistance, which may  suggest interplay
etween these enzymes.
Since KDM5A is found in complexes harboring HDACs, also
educed levels of acetylated histone H3 lysine 14 (H3K14ac) were
ound in TKI resistant cells. In line with these observations, drug-
esistant cells of various tumor cell lines were extremely sensitive
o RNA-interference-mediated inactivation of KDM5A or phar-
acological inhibition of KDM5A-associated HDACs, while the
arental tumor cell lines remained unaffected. Consequently, treat-
ent of these cell lines with a combination of TKI and HDACi
revented the development of drug resistance. Although it remains
nclear what drives the expression of KDM5A in EGFR TKI resis-
ant cells, these results provided important molecular insight into
he epigenetic mechanisms underlying drug resistance and simul-
aneously yield an exiting therapeutic approach to counteract
cquired drug resistance (Fig. 3B and C).
The difference in HDACi sensitivity between the parental and
rug-resistant cells could be explained by a differential DNA-
amage response. In contrast to the parental cell population,
DACi induced -H2AX, a marker of DNA damage, only in drug-
esistant cells in a checkpoint-dependent manner. How reduced
3K4 methylation and acetylation cause drug resistance and sen-
itize drug-resistant cells for HDACi-induced DNA damage remains
nclear. Treatment of tumor cells with HDACi prior to incubation
ith EGFR TKI did not reduce drug resistance, probably because
on-resistant cells constantly generate drug-resistant cells. These
bservations illustrate the dynamic nature of a tumor population
nd are in line with other studies addressing the plasticity of tumor
ell populations (Gupta et al., 2011).
Remarkably, inhibitors of the insulin growth factor 1 receptor
IGF-1R) severely suppressed drug-resistant outgrowth in com-
ination with EGFR TKI, cisplatin and BRAF inhibitor treatment.
rug-resistant cells displayed increased IGF binding protein 3
IGFBP3), as well as increased IGF-1R phosphorylation providing
 rational for the inhibitory effects of IGF-1R inhibitors. Even more
nteresting, IGF-1R inhibitors reduced KDM5A levels and concomi-
antly increased H3K4me2 levels, suggesting a direct link between
he IGF signal transduction pathway and KDM5A. Although the
ause and direction of the relationship between KDM5A and IGF
ignaling in drug-resistant cells is unclear, the IGF-1R pathway
as been linked to drug resistance and poor prognosis in var-
ous malignancies (Casa et al., 2008; Pollak, 2008). The rise of
rug-resistant cells in the presence of EGFR TKI and an IGF-1R
nhibitor harboring secondary genetic mutations in EGFR indi-
ated that drug resistance through genetic means is still selected
or (Sharma et al., 2010) (Fig. 3C). Therefore, the design of treat-
ent modalities that circumvent selection pressure for second
ite mutations in the drug target will be important to prevent
enetic-based drug resistance. In general, combining chemother-
py or targeted drugs to eradicate the majority of the tumor cells
“debulking”) with epigenetic drugs such as HDACi, DNMTi, BETi,
r inhibitors of pathways affected by a drug-resistant epigenome
inhibitors of IGF-1R, MGMT,  MLH1) may  inform future anti-
ancer treatment regimens to prevent tumor relapse (Fig. 3D
nd E).istance Updates 15 (2012) 21– 38
Nuclear cloning has taught us that differentiated cells can be
reprogrammed into pluripotent stem cells by erasing the epigenetic
memory that drives a particular phenotype. In a similar fashion the
studies mentioned above teach us that drug-resistant cells can be
reprogrammed into drug-sensitive cells by erasing the epigenetic
memory that dictates a drug-resistant phenotype using epigenetic
drugs.
9. Future perspectives
To increase the survival rates of cancer patients will be impos-
sible without improving the efﬁcacy of cytotoxic and targeted
anti-cancer drugs. Since drug resistance is the major cause of
treatment failure it will be vital to avoid non-responsiveness
toward current and future treatment modalities. The important
contribution of DNA- and histone modiﬁcations in drug resistance
implicates the possibility to prevent or abolish drug resistance by
reverting the cancer epigenome of non-responsive cells to a drug
responsive state. The development of various “epigenetic” drugs
will provide us with the tools for studying the reversibility of
drug resistance in vitro, in mouse models and clinical trials. Still,
our understanding of the epigenetic mechanisms that drive cells
into a drug-resistant state is in its infancy and requires additional
research (Table 1). Efforts in charting the epigenome of normal and
diseased cells will provide a platform to obtain insight into the
drug resistance epigenome (Abbott, 2011; American Association
for Cancer Research, 2008). However, the epigenome of a tumor
biopsy or primary tumor cell line will only provide the aver-
age of a heterogeneous tumor cell population, which does not
reﬂect a drug-resistant epigenome. Therefore, it will be impera-
tive to determine the epigenetic landscape of the rare population
of drug-resistant cells in order to identify the histone modiﬁers and
nucleosome remodelers that render anti-cancer drugs ineffective.
The results obtained from these studies will allow the design of
new and enhanced drugs that change the epigenetic landscape of
non-genetic drug-resistant cells to a drug sensitive state.
Furthermore, it will be key to identify the transcriptional
targets or non-histone substrates sufﬁcient to sustain the drug-
resistant state. The use of loss-of-function or gain-of-function
genetic screens has shown the ability to uncover factors under-
lying acquired drug resistance (Huang et al., 2009; Mullenders and
Bernards, 2009). Finally, the design of anti-cancer therapies that
combine tumor debulking strategies using cytotoxic or targeted
drugs with drug sensitivity inducing “epigenetic drugs” (Fig. 3) will
allow us to attack a heterogeneous tumor cell population from mul-
tiple angles, thereby minimizing the chance for drug-resistant cells
to escape and generate a drug-resistant tumor.
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